CytoMed Therapeutics
🇸🇬Singapore
- Country
- 🇸🇬Singapore
- Ownership
- -
- Employees
- 34
- Market Cap
- $18.3M
- Introduction
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.
CytoMed and SunAct Partner to Advance Gamma Delta T-Cell Therapy for Solid Tumors in India
• CytoMed Therapeutics and SunAct Cancer Institute collaborate to evaluate allogeneic gamma delta T cells for solid tumor treatment in a Phase 2 trial.
• The trial will assess the safety, tolerability, potency, and efficacy of CytoMed's cell therapy across various solid cancer types.
• CytoMed will provide technical support and manufacture the cell therapy, while SunAct will offer local expertise and access to patients in India.
• This collaboration aims to provide an affordable cancer treatment option and contribute to the global data pool for cancer research.
CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells
CytoMed Therapeutics, a Singapore-based biotech company, is pioneering a new approach to cancer treatment through its ANGELICA clinical trial. Utilizing donor immune cells, specifically gamma-delta T cells, CytoMed aims to offer a quicker, more affordable, and effective treatment for a broad range of cancers. This innovative method contrasts with traditional CAR T-cell therapy by using healthy donor cells, potentially making treatments available 'off-the-shelf'. The company is also exploring the use of its technology in longevity research and autoimmune diseases, marking a significant advancement in personalized targeted medicine.
CytoMed Therapeutics Initiates Phase I Trial of CTM-ONC in Solid Tumors
• CytoMed Therapeutics has begun its Phase I ANGELICA trial, evaluating CTM-ONC in patients with advanced solid tumors.
• The trial utilizes CytoMed's patented donor-derived allogeneic cell therapy platform to enhance safety and efficacy.
• CTM-ONC targets tumors expressing high levels of certain activating ligands, aiming to improve patient outcomes.
• This first-in-human study marks a significant step for CytoMed in developing innovative cancer immunotherapies.
CytoMed Therapeutics' ANGELICA Trial Receives Approval for Phase I Study in Advanced Cancers
• CytoMed Therapeutics has received full approval for its Phase I ANGELICA trial, evaluating allogeneic CAR-T cell therapy in advanced cancers.
• The ANGELICA trial uses gamma delta T cells from healthy donors, potentially improving CAR-T cell quality and reducing production costs.
• The trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council (NMRC) and involves collaboration with the National University Hospital (NUH).
• Part 2 of the ANGELICA trial will proceed with the recruitment of patients with advanced cancers resistant to standard therapy regimens.
Canadian-Developed CAR T-Cell Therapy Targeting CD22 Heads to Clinical Trials
• The National Research Council of Canada has developed a novel CAR T-cell therapy targeting the CD22 protein on B-cell leukemia and lymphoma cells, offering hope for patients who failed previous CD19-targeted treatments.
• Clinical trials for this made-in-Canada therapy are expected to begin in late 2023 across Vancouver, Ottawa, and Toronto, focusing on both pediatric and adult lymphoblastic leukemia and lymphoma patients.
• The NRC's approach aims to establish domestic biomanufacturing facilities across Canada, potentially making CAR T-cell therapies more affordable and accessible compared to current imported options that come with high costs and long wait times.
© Copyright 2025. All Rights Reserved by MedPath